Clinical trials: Medullary Thyroid Cancer
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging.
- Conditions
- Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06141369
- Testing
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Amyloid, Medullary Thyroid Cancer
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis
Using excess tumour samples that contain amyoid, from patients with Medullary Thyroid Cancer, we aim to determine the structures of ex vivo amyloid fibrils from human tumour tissue samples and compare them with that of existing…
- Conditions
- Amyloid, Medullary Thyroid Cancer, Alzheimer Disease, Dementia
- Trial name
- NCT04760171
- Volunteers
- 10 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Thyroid Cancer, Nonmedullary, Colon Carcinoma
Trained Immunity in Thyroid Carcinoma and Colon Carcinoma
Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator which is involved in the pathogenesis of both thyroid carcinoma and colon carcinoma.
- Trial name
- NCT05280379
- Testing
- no intervention will take place
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- Radboud University Medical Center
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic).
- Conditions
- Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT03587662
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Gemcitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Medullary Thyroid Cancer (MTC), Cultural Adaptation
Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer
To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help.
- Trial name
- NCT07142005
- Testing
- Interviews
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Sporadic Medullary Thyroid Cancer
Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib
Vandetanib has been approved for patients with unresectable and/or metastatic medullary thyroid cancer (MTC) by the Food and Drug Administration, by the European Medicines Agency and, very recently, it has been licensed also by…
- Trial name
- NCT02268734
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase II, Sacituzumab
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.
- Conditions
- Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary Carcinoma
- Trial name
- NCT07438626
- Testing
- Sacituzumab tirumotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Medullary Thyroid Cancer, Medullary Carcinoma
Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
The oncologic benefit of lateral neck dissection (LND) during index operation for sporadic medullary thyroid carcinoma (MTC) basing on basal calcitonin (bCT) levels has been questioned due to the potential post-operative…
- Conditions
- Medullary Thyroid Cancer, Medullary Carcinoma, Medullary Tumor, Medullary Neoplasms
- Trial name
- DSR-MTC (NCT06243965)
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic).
- Conditions
- Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma
- Trial name
- NCT01767636
- Testing
- Pazopanib Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Hypercalcemia, Familial Primary Hyperparathyroidism
Cinacalcet to Treat Familial Primary Hyperparathyroidism
This study will evaluate the benefits and side effects of a new medication called Cinacalcet for treating patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 (MEN1) or type 2A (MEN2A).
- Trial name
- NCT00325104
- Testing
- Parathyroid hormone testing, Serum calcium testing
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recurrent Malignant Solid Neoplasm, Recurrent Melanoma
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment.
- Conditions
- Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Thyroid Gland Carcinoma
- Trial name
- NCT01709435
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 23 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Medullary Thyroid Cancer
Predictive Factors for Medullary Thyroid Cancer Aggressiveness
This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival.
- Trial name
- MYELO (NCT06292988)
- Testing
- Total Thyroidectomy
- Where
- 46 sites in United States, Austria and 22 more
- Volunteers
- 500 people
- Sponsor
- Aristotle University Of Thessaloniki
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
Medullary Thyroid Cancer
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
A mono centre study to evaluate the efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.
- Trial name
- NCT01625520
- Testing
- SOM230 alone or in combination with RAD001.
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Federico II University
Carcinoid Cancer, Neuroendocrine Tumors
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
- Conditions
- Carcinoid Cancer, Neuroendocrine Tumors, Medullary Thyroid Cancer, Cancers Expressing Somatostatin Receptors
- Trial name
- NCT02174679
- Testing
- 68Ga DOTATATE
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Head and Neck Cancer
Thalidomide in Treating Patients With Thyroid Cancer
RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.
- Trial name
- NCT00026533
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Kenneth Ain
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.